Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.
Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M. Ciuffreda L, et al. Among authors: falcone i. J Mol Med (Berl). 2012 Jun;90(6):667-79. doi: 10.1007/s00109-011-0844-1. Epub 2012 Jan 4. J Mol Med (Berl). 2012. PMID: 22215152
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M. Vari S, et al. Among authors: falcone i. Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3. Expert Opin Drug Discov. 2013. PMID: 24088065 Review.
Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC.
Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA, Milella M. Ciuffreda L, et al. Among authors: falcone i. Curr Pharm Des. 2014;20(24):3944-57. doi: 10.2174/13816128113196660763. Curr Pharm Des. 2014. PMID: 24138714 Review.
PTEN: Multiple Functions in Human Malignant Tumors.
Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L. Milella M, et al. Among authors: falcone i. Front Oncol. 2015 Feb 16;5:24. doi: 10.3389/fonc.2015.00024. eCollection 2015. Front Oncol. 2015. PMID: 25763354 Free PMC article. Review.
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L. Milella M, et al. Among authors: falcone i. Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013. Sci Rep. 2017. PMID: 28220839 Free PMC article.
mTOR Cross-Talk in Cancer and Potential for Combination Therapy.
Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M. Conciatori F, et al. Among authors: falcone i. Cancers (Basel). 2018 Jan 19;10(1):23. doi: 10.3390/cancers10010023. Cancers (Basel). 2018. PMID: 29351204 Free PMC article. Review.
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L. Del Curatolo A, et al. Among authors: falcone i. J Exp Clin Cancer Res. 2018 Jul 9;37(1):140. doi: 10.1186/s13046-018-0820-5. J Exp Clin Cancer Res. 2018. PMID: 29986755 Free PMC article.
38 results